CY1115504T1 - Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη - Google Patents
Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινηInfo
- Publication number
- CY1115504T1 CY1115504T1 CY20141100686T CY141100686T CY1115504T1 CY 1115504 T1 CY1115504 T1 CY 1115504T1 CY 20141100686 T CY20141100686 T CY 20141100686T CY 141100686 T CY141100686 T CY 141100686T CY 1115504 T1 CY1115504 T1 CY 1115504T1
- Authority
- CY
- Cyprus
- Prior art keywords
- complexes
- platinum
- cisplatin
- phosphoplatin
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 3
- KTCQVFPGCRGZPS-UHFFFAOYSA-N P(=O)(=O)[Pt] Chemical compound P(=O)(=O)[Pt] KTCQVFPGCRGZPS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229960004562 carboplatin Drugs 0.000 abstract 2
- 190000008236 carboplatin Chemical compound 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- PVGAVTXIFQJKJI-UHFFFAOYSA-H platinum(2+);diphosphate Chemical compound [Pt+2].[Pt+2].[Pt+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O PVGAVTXIFQJKJI-UHFFFAOYSA-H 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| EP08797320.2A EP2173337B1 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115504T1 true CY1115504T1 (el) | 2017-01-04 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100686T CY1115504T1 (el) | 2007-08-06 | 2014-08-27 | Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (enExample) |
| EP (2) | EP2173337B1 (enExample) |
| JP (2) | JP5385274B2 (enExample) |
| CN (1) | CN101801369B (enExample) |
| CY (1) | CY1115504T1 (enExample) |
| DK (1) | DK2173337T3 (enExample) |
| ES (1) | ES2495743T3 (enExample) |
| HR (1) | HRP20140808T1 (enExample) |
| PL (1) | PL2173337T3 (enExample) |
| PT (1) | PT2173337E (enExample) |
| SI (1) | SI2173337T1 (enExample) |
| WO (2) | WO2009021081A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801369B (zh) | 2007-08-06 | 2012-09-19 | 俄亥俄大学 | 磷铂及其在治疗顺铂和卡铂耐药性癌中的用途 |
| PT2575802T (pt) * | 2010-06-04 | 2016-12-27 | Univ Ohio | Fosfaplatinas e sua utilização para o tratamento de cancros |
| CA2818933A1 (en) * | 2011-01-12 | 2012-07-19 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| WO2013009511A1 (en) | 2011-07-08 | 2013-01-17 | Dow Global Technologies Llc | Polyethylene blend composition suitable for blown film, method of producing the same, and films made therefrom |
| JP6027619B2 (ja) | 2011-10-05 | 2016-11-16 | ラシンドラ・エヌ・ボーズ | ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス |
| CA2851254A1 (en) * | 2011-10-05 | 2013-04-11 | The University Of Houston System | Efficient processes for large scale preparation of phophaplatins antitumor agents |
| AU2012325819B2 (en) | 2011-10-20 | 2017-08-03 | Nerium Biotechnology, Inc. | Therapeutic combination for the treatment of cancer |
| EP2855496B1 (en) * | 2012-05-24 | 2016-12-14 | Phosplatin Therapeutics LLC | Synthetic and purification methods for phosphaplatin compounds and uses thereof |
| WO2014130776A1 (en) | 2013-02-22 | 2014-08-28 | University Of Houston | Phosphaplatins as neuroprotective agents |
| US20150231151A1 (en) * | 2014-02-19 | 2015-08-20 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| KR102412203B1 (ko) | 2014-06-11 | 2022-06-23 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물 |
| WO2017116356A1 (en) | 2015-12-30 | 2017-07-06 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| KR102718532B1 (ko) * | 2017-01-06 | 2024-10-21 | 프로몬토리 테라퓨틱스 인코포레이티드 | 뼈 또는 혈액 암의 치료를 위한 치료제로서의 포스파플라틴 화합물 |
| JP7381083B2 (ja) * | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291027A (en) * | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Engelhard Corporation | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| WO2005000858A2 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
| WO2009008345A1 (ja) * | 2007-07-06 | 2009-01-15 | Tmrc Co., Ltd. | 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体 |
| CN101801369B (zh) | 2007-08-06 | 2012-09-19 | 俄亥俄大学 | 磷铂及其在治疗顺铂和卡铂耐药性癌中的用途 |
-
2008
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
- 2008-08-06 HR HRP20140808AT patent/HRP20140808T1/hr unknown
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Ceased
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en not_active Ceased
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2173337A4 (en) | 2010-10-27 |
| US7700649B2 (en) | 2010-04-20 |
| JP2013227218A (ja) | 2013-11-07 |
| EP2173337A2 (en) | 2010-04-14 |
| ES2495743T3 (es) | 2014-09-17 |
| US20110313182A1 (en) | 2011-12-22 |
| US8445710B2 (en) | 2013-05-21 |
| SI2173337T1 (sl) | 2014-10-30 |
| DK2173337T3 (da) | 2014-09-15 |
| PL2173337T3 (pl) | 2014-11-28 |
| WO2009021082A3 (en) | 2009-04-23 |
| JP5647300B2 (ja) | 2014-12-24 |
| JP5385274B2 (ja) | 2014-01-08 |
| WO2009021081A3 (en) | 2009-05-07 |
| CN101801369A (zh) | 2010-08-11 |
| US20090042838A1 (en) | 2009-02-12 |
| US20130237503A1 (en) | 2013-09-12 |
| PT2173337E (pt) | 2014-09-03 |
| US8653132B2 (en) | 2014-02-18 |
| EP2173337B1 (en) | 2014-07-30 |
| US8034964B2 (en) | 2011-10-11 |
| JP2010535803A (ja) | 2010-11-25 |
| WO2009021081A2 (en) | 2009-02-12 |
| CN101801369B (zh) | 2012-09-19 |
| HRP20140808T1 (hr) | 2014-10-24 |
| HK1143551A1 (en) | 2011-01-07 |
| EP2668949A1 (en) | 2013-12-04 |
| WO2009021082A2 (en) | 2009-02-12 |
| US20100233293A1 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009021081A3 (en) | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin | |
| Hickey et al. | Mitochondria-targeted chemotherapeutics: the rational design of gold (I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols | |
| Li et al. | Half-sandwich iridium and ruthenium complexes: effective tracking in cells and anticancer studies | |
| Braga et al. | A new age for iron: antitumoral ferrocenes | |
| CY1122855T1 (el) | Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου | |
| Ban et al. | Boron‐based drug design | |
| Brabec | DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair | |
| Arjmand et al. | Progress of Metal‐Based anticancer chemotherapeutic agents in last two decades and their comprehensive biological (DNA/RNA Binding, Cleavage and Cytotoxicity Activity) studies | |
| Panchangam et al. | Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer | |
| Hanif et al. | A multitargeted approach: organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor | |
| CY1114040T1 (el) | Συνδυαστικη θεραπεια του καρκινου περιλαμβανουσα αναστολεις των egfr/her2 | |
| Mitra et al. | Biotinylated platinum (II) ferrocenylterpyridine complexes for targeted photoinduced cytotoxicity | |
| EA201000994A2 (ru) | Химически модифицированные малые молекулы | |
| Mehmood et al. | Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective | |
| CY1112052T1 (el) | Γονιδια και πολυπεπτιδια που σχετιζονται προς τους καρκινους ανθρωπινων κολον | |
| Pettinari et al. | From sunscreen to anticancer agent: Ruthenium (II) arene avobenzone complexes display potent anticancer activity | |
| Sahu et al. | LVVO-ethyl Maltol-based Metallodrugs (L2–= tridentate ONO ligands): hydrophobicity, hydrolytic stability, and cytotoxicity via ROS-mediated apoptosis | |
| McGivern et al. | Innovative DNA-targeted metallo-prodrug strategy combining histone deacetylase inhibition with oxidative stress | |
| Meng et al. | Synthesis and biological evaluation of substituted 3-(2′-benzimidazolyl) coumarin platinum (II) complexes as new telomerase inhibitors | |
| Nano et al. | Rhodium complexes targeting DNA mismatches as a basis for new therapeutics in cancers deficient in mismatch repair | |
| Clemente et al. | Platinacycles containing a primary amine platinum (II) compounds for treating cisplatin-resistant cancers by oxidant therapy | |
| Wang et al. | Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin | |
| Michlewska et al. | Ruthenium dendrimers against acute promyelocytic leukemia: In vitro studies on HL-60 cells | |
| Khan et al. | New ionic Cu (II) and Co (II) DACH–flufenamate conjugate complexes: spectroscopic characterization, single x–ray studies and cytotoxic activity on human cancer cell lines | |
| Sethupathi et al. | Macrocyclic “tet a”-Derived Cobalt (III) Complex with a N, N′-Disubstituted Hexadentate Ligand: Crystal Structure, Photonuclease Activity, and as a Photosensitizer |